Enspryng(satralizumab)
Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| eye diseases | D005128 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Enspryng
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enspryng | Biologic Licensing Application | 2023-07-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| neuromyelitis optica | EFO_0004256 | D009471 | G36.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
satralizumab, Enspryng, Genentech, Inc. | |||
| 2027-08-14 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | 4 | 1 | 2 | 7 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | 2 | — | — | 2 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | 2 | — | — | 2 |
| Thyroid diseases | D013959 | — | E00-E07 | — | — | 2 | — | — | 2 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | — | — | 1 | — | — | 1 |
| Muscle weakness | D018908 | — | — | — | — | 1 | — | — | 1 |
| Autoimmune diseases of the nervous system | D020274 | — | — | — | — | 1 | — | — | 1 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | 1 | — | — | 1 |
| Encephalitis | D004660 | — | — | — | — | 1 | — | — | 1 |
| Partial epilepsies | D004828 | EFO_0004263 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | 2 | — | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | 1 | — | — | — | 1 |
| Facioscapulohumeral muscular dystrophy | D020391 | EFO_0000491 | G71.02 | — | 1 | — | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | — | — | — | — | 1 |
| Cerebral infarction | D002544 | — | I63 | 1 | — | — | — | — | 1 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Demyelinating diseases | D003711 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Satralizumab |
| INN | satralizumab |
| Description | Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1535963-91-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3833307 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15762 |
| UNII ID | YB18NF020M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Enspryng – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 583 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
957 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use